mTOR ATP-competitive inhibitor INK128 inhibits neuroblastoma growth via blocking mTORC signaling

Decision-making by p53 and mTOR

(2016) Carl G. Maki   Aging-US

MRS and MRSI guidance in molecular medicine: targeting and monitoring of choline and glucose metabolism in cancer

(2015) Kristine Glunde et al.   NMR IN BIOMEDICINE

Striking dichotomy in outcome ofMYCN-amplified neuroblastoma in the contemporary era

(2014) Brian H. Kushner et al.   CANCER

Rapamycin: One Drug, Many Effects

(2014) Jing Li et al.   Cell Metabolism

Sunitinib Suppress Neuroblastoma Growth through Degradation of MYCN and Inhibition of Angiogenesis

(2014) Raul Calero et al.   PLoS One

A small-molecule inhibitor of UBE2N induces neuroblastoma cell death via activation of p53 and JNK pathways

(2014) J Cheng et al.   Cell Death & Disease

Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway

(2013) Howard A. Burris   CANCER CHEMOTHERAPY AND PHARMACOLOGY

USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis

(2013) Y-H Fan et al.   Cell Death & Disease

The ALKF1174L Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma

(2012) Teeara Berry et al.   CANCER CELL

mTOR Signaling in Cancer Cell Motility and Tumor Metastasis

(2012) Hongyu Zhou et al.   CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION

Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia

(2012) M R Janes et al.   LEUKEMIA

Targeting mTOR with rapamycin: One dose does not fit all

(2011) David A. Foster et al.   CELL CYCLE

Targeting mTOR globally in cancer: Thinking beyond rapamycin

(2011) Boris Shor et al.   CELL CYCLE

ATP-Competitive Inhibitors of mTOR: An Update

(2011) S. Schenone et al.   CURRENT MEDICINAL CHEMISTRY

mTOR signaling in disease

(2011) Eva Dazert et al.   CURRENT OPINION IN CELL BIOLOGY

The dual PI3K/mTOR inhibitor NVP-BGT226 induces cell cycle arrest and regulates Survivin gene expression in human pancreatic cancer cell lines

(2011) Wolfgang Glienke et al.   TUMOR BIOLOGY

Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment

(2010) Carlos García-Echeverría   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Genetic Dissection of the Oncogenic mTOR Pathway Reveals Druggable Addiction to Translational Control via 4EBP-eIF4E

(2010) Andrew C. Hsieh et al.   CANCER CELL

Neuroblastoma: Therapeutic strategies for a clinical enigma

(2010) Shakeel Modak et al.   CANCER TREATMENT REVIEWS

New inhibitors of the mammalian target of rapamycin signaling pathway for cancer

(2010) Sébastien Albert et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Combination of tipifarnib and rapamycin synergistically inhibits the growth of leukemia cells and overcomes resistance to tipifarnib via alteration of cellular signaling pathways

(2010) Tadashi Nagai et al.   LEUKEMIA RESEARCH

Myc proteins as therapeutic targets

(2010) W C Gustafson et al.   ONCOGENE

Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy

(2010) C A Sparks et al.   ONCOGENE

mTOR pathway inhibitors in cancer therapy: moving past rapamycin

(2010) Volker Wacheck   PHARMACOGENOMICS

Dissecting the role of mTOR: Lessons from mTOR inhibitors

(2009) Ryan J.O. Dowling et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

The PI3K/Akt/mTOR Pathway as Therapeutic Target in Neuroblastoma

(2009) S. Fulda   CURRENT CANCER DRUG TARGETS

Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma

(2008) Anne-Christine Piguet et al.   JOURNAL OF HEPATOLOGY

Hypersensitivity of Ph-positive lymphoid cell lines to rapamycin: Possible clinical application of mTOR inhibitor

(2008) Chikara Hirase et al.   LEUKEMIA RESEARCH